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Adeno-associated virus (AAV) is an important vector system for human gene therapy. Although use of AAV
serotypes can result in efficient myocardial gene transfer, improvements in the transduction efficiency and
specificity are still required. As a method for artificial modification and selection of gene function, directed
evolution has been used for diverse applications in genetic engineering of enzymes and proteins. Since 2000,
pioneering work has been performed on directed evolution of viral vectors. We further attempted to evolve the
AAV using DNA shuffling and in vivo biopanning in a mouse model. An AAVM41 mutant was characterized, which
was found to have improved transduction efficiency and specificity in myocardium, an attribute unknown for any
natural AAV serotypes. This review focuses on the development of AAV vector for cardiac gene transfer, the history
of directed evolution of viral vectors, and our creation of a cardiotropic AAV, which might have implications for the
future design and application of viral vectors.
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The adeno-associated virus (AAV) is one of the smallest
viruses, with a non-enveloped capsid measuring approxi-
mately 22 nm. It has a linear single-stranded DNA gen-
ome of 4.7 kb in size, which is composed of three gene
elements: rep, which encodes the replication proteins;
cap, which encodes the capsid proteins; and ITR, which
serves as the replication origin and packaging signal
(Figure 1). The cap gene is transcribed from a single p40
promoter, but produces three virion proteins VP1, VP2,
and VP3, which differ in length from each other because
of the different location of their initiation codons. These
three proteins have molecular masses of 87, 72, and
62 kDa, respectively, and they assemble in a molar ratio
of 1:1:10 to form a near-spherical protein shell of 60
subunits. Despite the fact that an alternative product of
the cap gene, associated with the assembly of the AAV
particle has been characterized [1], only the three capsid
proteins mentioned above are mainly responsible for the
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reproduction in any medium, provided the orDespite its prevalence rate of approximately 80% in
human populations, AAV has not been linked to any
human illness, and has thus been used as a vector to carry
DNA into cells. AAV transduces cells via a multi-step con-
secutive course [2,3]. The virus initially binds to the recep-
tor/co-receptor on surface of the cell, and penetrates into
it via receptor-mediated endocytosis. The virion is trans-
ported through the endosomal compartment, and most
likely escapes into the nucleus through the nuclear pore
complex via an as yet unknown mechanism. After nuclear
translocation, the capsid uncoats, releasing single-stranded
DNA, which is converted into double-stranded DNA for
transgene expression. The majority of the AAV vector
genomes exist as episomes in the transduced cells [4],
which ensures the stable expression of the transgene in
post-mitotic tissues (e.g., neuron and muscle) with a lower
risk of carcinogenesis. Furthermore, the AAV vector itself
elicits only a relatively weak innate and acquired immune
response in the hosts [5], which affirms the tolerated trans-
gene expression and the higher safety profile in gene ther-
apy. These two biologic features mean that AAV has great
potential as a vector for human gene therapy.
The safety and efficacy of AAV-mediated gene therapy
were first verified in clinical trials investigating nervous
diseases. Sub-retinal delivery of AAV carrying the gene foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Modification of adeno-associated virus (AAV) cap gene by DNA shuffling. The cap genes of eight AAV serotypes were amplified
and mixed together in the same ratio. They were then fragmented by transient DNase I treatment. The small DNA fragments were reassembled
by primerless PCR and homologous recombination were introduced in this step. Lastly, the full-length cap genes were amplified and inserted
into the plasmid vector with AAV2 rep gene and ITR sequences for generation of plasmid and virus libraries.
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(RPE65) was verified by several studies to be safe and ef-
fectively improve retinal function in patients with Leber’s
congenital amaurosis [6-8]. Gene transfer of glutamic acid
decarboxylase via AAV into the subthalamic nucleus of
subjects with Parkinson’s disease was well tolerated, and
significantly improved the clinical scores of the subjects
[9]. More recent clinical trials have expanded the applica-
tion of the AAV vector to gene therapy of muscular
diseases. Calcium upregulation was achieved by intracor-
onary administration of an AAV1/sarcoplasmic reticulum
Ca2+-ATPase vector; the study demonstrated safety and
suggested a benefit in the patients of advanced heart
failure [10]. Long-term, sustainable alpha-sarcoglycan ex-
pression of was detected in the muscles of patients with
limb-girdle muscular dystrophy following AAV1-mediated
gene transfer regulated by the muscle-specific tMCK pro-
moter [11] (more detailed documentation of current pro-
gress in clinical trials using AAV vectors can be found in
the review by Mingozzi and High [12]).
Despite the numerous advantages of AAV for gene
transfer, several flaws remain to be addressed to improve
the versatility of this viral vector. In this review, we pro-
vide an introduction to the development of AAV vector
for myocardial gene transfer, and focus on how a cardio-
tropic AAV was created using the directed evolution
strategy. The related progress of directed evolution is
reviewed to provide a background to this discovery.
Why is a cardiotropic AAV needed? The evolution of AAV
vector biology
For historic reasons, the serotype 2 (AAV2) was the first
AAV used as a gene-therapy vector and for detailedbiological studies [13]. The AAV2 genome was shown to
exist in transduced mouse skeletal muscle as concatamers,
and the transgene expression persisted for 1.5 years with-
out induction of humoral or cellular immune responses
[14,15]. Immediately following this research, AAV2 began
to be used for transduction of myocardium in animals. In
contrast to the transient transgene expression from
adenovirus transduction, up to 50% of mouse cardiomyo-
cytes were found to be positively transduced 4–8 weeks
after intramyocardial injection or coronary artery perfu-
sion with AAV2 [16]. Further studies applied the AAV2
vector to therapeutic gene transfer for the treatment of
various heart diseases such as myocardial infarction
[17,18], dilated cardiomyopathy [19], and dystrophic car-
diomyopathy [20]. Generally, these gene-therapy trials
yielded favorable results, with stable and efficient trans-
gene expression achieved in the animal myocardium.
In addition to AAV2, a number of AAV serotypes have
been successively identified and their attributes charac-
terized for cardiac gene transfer [21]. Of the known
serotypes, AAV1 and AAV6 appeared to transduce the
rodent myocardium most promptly and efficiently by
direct intramyocardial injection [22,23]. Accordingly,
AAV6 has been used for delivery of betaARKct, a pep-
tide capable of inhibiting activation of G protein-coupled
receptor kinase 2 into rats with heart failure, resulting in
a significant improvement of cardiac contractility and re-
versal of left ventricular remodeling [24]. AAV6 was also
first successfully employed to achieve widespread trans-
duction of cardiac and skeletal muscles in adult mice by
intravenous administration supplemented with vascular
permeability factor [25]. A further technical advancement
occurred with the use of AAV8, which appeared to be
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rier than AAV6, and efficiently transduced heart and skel-
etal muscles in mice and hamsters without assistance of
vascular permeability factor [26,27]. More recently, AAV9
was shown to have an even higher transduction efficiency
in mouse myocardium following intravenous injection
[28], and a similar result was observed in non-human
primates [29]. Notably, the myocardial transduction effi-
ciency of these AAV serotypes were further validated in
different heart disease models via systemic delivery
[27,30-32]. These studies built a foundation for further
application of AAV vectors to translational medicine.
Such studies on various AAV serotypes have greatly
improved the performance of the AAV vector in myocar-
dial gene transfer. However, all of the known AAV sero-
types tend to transduce the liver preferentially when
administered in vivo, especially with systemic infusion.
This feature is a barrier to safe and efficient cardiac gene
transfer in human beings, as transduction of unintended
organs might result in unnecessary toxicity and immune
response. Fortunately, researchers have begun to address
this issue, using a variety of approaches. Müller et al.
modified the AAV2 capsid by introduction of R484E and
R585E mutations to the heparin sulfate proteoglycan
binding sites, which improved the specificity of cardiac
transduction by AAV vector to some extent [33]. Asokan
et al. generated a chimera AAV2i8 by replacing the hex-
apeptide sequence in the heparan sulfate receptor foot-
print of AAV2 with that of AAV8 [34]. AAV2i8 selectively
transduced cardiac and whole-body skeletal muscle tissues
with high efficiency, and showed markedly reduced hep-
atic tropism. However, it still appears challenging to im-
prove the cardiac transduction of AAV vector as well as to
detarget it from liver and other unintended organs. We
hypothesized that the directed evolution approach might
be an option to achieve this aim because of its highly di-
verse and flexible applications. The related hypothesis and
techniques are documented below.
How can a cardiotropic AAV be created? Hypothesis and
techniques for directed evolution of AAV
AAV is a parvovirus that exhibits some unusual evolu-
tionary features. In a series of investigations on evolution
of non-human primate AAV, the AAV cap genes were
found to exhibit unexpectedly high levels of gene diver-
sity [35,36]. Furthermore, this sequence diversity was
caused in part by homologous recombination of co-
infecting parental viruses that modified the serologic re-
activity and tropism of the virus. These studies not only
shed light on the evolutionary mechanism for genetic
variation in the AAV genome, but also served as the hy-
pothesis for our research on directed evolution of AAV,
i.e., that modification of the AAV cap genes by homolo-
gous recombination could plausibly generate AAV variantswith novel tissue tropism. These references also indicated
that polymerase chain reaction (PCR) might be a more
sensitive molecular technique for retrieval of trace AAV
variants from animal tissues in comparison to the classic
virus isolation methods based on cell culture.
At the time we began our work, some pioneering stud-
ies had been carried out into directed evolution of a
retrovirus. Genetic recombination between six murine
leukemia viruses was achieved by DNA shuffling, and
the resulting virus library was selected using the non-
permissive CHOK1 cell line to evolve a completely new
tropism [37]. Directed evolution is a method of artifi-
cially modifying and selecting genes with desirable prop-
erties not found in nature. With respect to DNA
shuffling, it was a method originally invented by Stem-
mer to induce in vitro recombination between homolo-
gous genes by PCR (Figure 1) [38]. Sequence variants
from a gene or orthologous genes are treated with DNase
I to generate random DNA fragments. Using PCR amplifi-
cation with the homologous DNA as templates and pri-
mers reciprocally, these fragments are reassembled into
genes of the same size as the original, but with variable
functions. Homologous recombination between the DNA
fragments occurs, and the reassembled genes are eventu-
ally cloned for selection on a biological platform for the
specific functions required. Although directed evolution
had been used previously to engineer proteins or enzymes,
the work of Soong and his colleagues on retrovirus was
the first attempt to evolve a gene within the framework of
a virus, which expanded the biological application of this
technique in biomedicine [37].
One classic method to modify the tropism of a viral
vector was to insert a ligand on the virus surface to tar-
get the specific cell type. Initially, the targeting ligand
was isolated via an indirect approach such as peptide
phage display, and then inserted into the virus surface
for further characterization. Müller et al. were the first
to attempt direct display of a random peptide library on
the AAV surface to select the endothelial-cell-targeting
ligands [39]. The peptide library was inserted after the
R588 site of the AAV capsid, in order to minimize steric
change and assure effective ligand exposition. The
authors ensured encoding of each displayed peptide by
the packaged DNA by using a two-step system for virus
library production. After screening on primary human
endothelial cells, the selected AAV with targeting pep-
tides exhibited enhanced transduction of coronary endo-
thelial cells but reduced infection of non-endothelial
cells. Although this work did not fall into the classic cat-
egory of directed evolution, it enriched the concept and
practice for diversification and screening of virus library.
The first AAV study using directed evolution in the
stricter sense was published by Maheshri et al. in 2006
[40]. In that work, the AAV2 cap gene was subjected to
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distribution of the 
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Figure 2 In vivo selection of adeno-associated virus (AAV) variants targeting special tissues. The AAV library with diversified cap genes
was injected into adult C57BL/6J mice via the tail vein. Genomic DNA was isolated from the target organs, i.e., the heart or skeletal muscle, and
used for PCR amplification of AAV cap genes. The selected cap gene mutants were re-cloned into plasmid vector with AAV rep gene and ITR
sequences. The generated plasmid libraries were used for sequence analysis of cap genes and production of AAV libraries for the next screening
cycle in mice. After a few rounds of in vivo biopanning, the cap genes enriched in the heart or skeletal muscle but relatively rare in the liver were
used for packaging of recombinant AAV vectors for characterization of their tissue tropism.
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to construct an AAV library with high capsid diversity.
The AAV library was eluted from a heparin-binding col-
umn, and AAV mutants with different heparin affinity
were separated by fractionation. In accordance with its
lower heparin affinity, one AAV mutant showed reduced
transduction efficiency when heparan sulfate binding be-
came limiting. In the second application, the AAV li-
brary was passaged in 293 cells after pre-incubation with
anti-AAV neutralizing serum. After two rounds of modi-
fication and selection, one AAV clone, r2.15, was found
to display a capacity to resist antibody neutralization
that was 96-fold higher than that of wild-type AAV2.
The modification methods and selection strategies used
in this study would exert an important influence on suc-
cessive directed evolution research on AAV.
What have we done? The modification and selection of
AAV vectors targeting heart and skeletal muscle
The original aim of our work was to modify the AAV
vector for efficient detargeting from liver to muscle. The
natural evolution of AAV urged us to use artificial evolu-
tion to mimic this course in order to improve the trans-
duction efficiency of AAV in striated muscles. As nine
AAV serotypes have now been successively identified, we
decided to select eight of these (AAV1–4, AAV6–9) for
DNA shuffling of the cap genes, as AAV5 cap genes has
been shown to have the largest sequence variation com-
pared with those of other AAV serotypes and might
lower the efficiency of in vitro recombination. We also
expected that using the natural AAV cap genes as par-
ents for DNA shuffling would ensure a higher viability
of the AAV progenies. The shuffled cap genes werecloned into a plasmid backbone with the AAV2 rep gene
and ITR sequences (Figure 1). Random clones were
picked from the plasmid library for examination of se-
quence variation and viability of the recombined AAV
cap genes. An AAV library was then produced, referring
to the two-step method described by Müller et al. [39].
The cap genotype and phenotype of each virus particle
were hyphothetically one-to-one correspondent, which
would facilitate the successive screening AAV library.
We used two models, one in vitro and the other
in vivo, for selection of AAV variants targeting muscles.
The in vitro model was composed of a microvascular
endothelial cell barrier and a differentiated myocyte
culture. The in vivo model was the C57BL/6J mouse,
which as an inbreeding strain has been universally used
for biomedical research. We hypothesized that the in vivo
model would be more realistic, as it should perfectly
mimic the physiological environment for the successive
gene therapy application of the AAV vector. We first
tested the in vivo model by using intravenous injection of
an AAV library into mice, followed by isolation of the
AAV variants from tissues using PCR (Figure 2). We were
able to retrieve the AAV cap genes from several mouse tis-
sues, including heart, skeletal muscle and liver, for genetic
analysis and reconstruction of the virus libraries. There-
fore, the C57BL/6J mouse model was appropriate for our
purpose to screen AAV variants that could bypass the
vascular barrier and infect muscles. When the virus li-
brary was injected intravascularly into the mice, we
were able to intentionally select those AAV variants pre-
ferentially infecting a specific organ, such as the heart.
Our aim was to select AAV variants targeting the heart
and skeletal muscle. Accordingly, following the first
Figure 3 The putative mechanism for different transduction efficiencies of adeno-associated virus (AAV) types AAV6 and AAVM41
vectors in mouse heart. These two vectors entered the cardiac tissues with the similar efficiency as a whole. However, AAVM41 might
preferentially transduce the cardiomyocytes whereas AAV6 tended to infect endothelial cells with the higher ratio. This discrepancy in tissue
distribution enabled AAVM41 to exhibit higher transduction efficiency of myocardium compared with AAV6 after systemic administration. Note
that the virus particles in the interior of the cells indicated only that these cells were positively transduced. The real intracellular localization and
viral structure of AAV are not reflected in this chart for simplicity.
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heart and skeletal muscle for reconstruction of the virus
libraries for the second screening in mice. The AAV cap
genes from the heart and skeletal muscle, respectively,
were then sequenced, and their gene frequencies were
compared with those from the liver. The AAV mutants
enriched in heart or skeletal muscle were selected for
further genetic analysis and tropism characterization.
Strikingly, we obtained a cardiotropic AAVM41 variant
from the mouse skeletal muscle [41]. This was not
completely unexpected, as cardiac and skeletal muscles
share a similar anatomical origin, and are both subor-
dinate to striated muscles. Our variant, AAVM41, exhib-
ited preferential tropism to mouse myocardium after
systemic administration, with a transduction level similar
to that of AAV9. However, gene transfer in non-muscle
tissues, mainly the liver, was dramatically reduced. This
higher affinity to heart rather than liver appeared to be a
unique feature of AAVM41, and has not been reported for
any naturally evolved AAV variant. Furthermore, the
therapeutic potential of AAVM41 was demonstrated by
delivery of the δ-sarcoglycan gene into the dystrophic TO-
2 hamster for efficient amelioration of cardiomyopathy.
It remains unclear as to how the AAVM41 vector
evolved its improved efficiency and specificity in myo-
cardial transduction. The sequence of the AAVM41 cap-
sid is closest to that of AAV1 and AAV6 [41]. It also had
the similar vector genome copies in the whole heart to
that of AAV6 after systemic vector administration. How-
ever, the myocardial transduction efficiency of AAVM41
was at least 10 times higher than that of AAV6. By con-
trast, AAV6 was superior to AAVM41 in directtransduction of primary cardiomyocytes in vitro. One
plausible interpretation is that AAV6 tends to infect both
endothelial cells and cardiomyocytes in the in vivo physio-
logical environment, whereas AAVM41 could bypass the
endothelial cells and preferentially infect the cardiomyo-
cytes when infused into blood stream (Figure 3). Because
it is the cardiomyocytes rather than the vascular endothe-
lial cells that occupy the major volume of the heart, this
would then account for the fact that AAVM41 generally
exhibited a higher transgene expression level in the myo-
cardium. It would be possible to test this hypothesis by
comparative study of the vector genome distribution of
these two AAV vectors in different cardiac cell types after
systemic administration. The recently developed quantita-
tive 3-D tracing microscopic technique will also be helpful
to elucidate the mechanism behind the improved cardiac
transduction of the AAVM41 vector [42].
Progress and prospects for directed evolution of AAV
Since the first report of directed evolution of AAV pub-
lished in 2006, a number of papers have been published
in this area. Researchers have designed various strat-
egies for modification of AAV to achieve diverse pur-
poses. Generally, the following development strategies
were used.
1. Combinatory application of multiple methods for
diversification of the AAV cap gene. The original
attempts to modify the AAV cap gene respectively
involved random peptide insertion [39], random
mutagenesis [40], and DNA shuffling [41]. In some
recent work on directed evolution, AAV libraries
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simultaneously screened in a suitable cell model. As a
result, the ShH19 mutant from combinatory libraries
produced by DNA shuffling and random mutagenesis
was shown to have the highest transduction
efficiency in rat astrocytes in vivo [43]. An AAV r3.45
variant with both a peptide insertion and a point
mutation was found to have the most efficient
transduction of neural stem cells [44]. These results
demonstrated the power of simultaneous utilization
of multiple gene diversification methods for efficient
direct evolution.
2. Realistic biological model for screening of AAV
library. In cases where a virus library with high gene
diversity has been constructed, the biological
platform is likely to be the determining factor for
successful directed evolution. An organotypic human
airway model was used to screen a virus library
produced by the diversification of AAV2 and AAV5
cap genes, and it was found that the AAV2.5 T
mutant yielded was able to mediate gene transfer
more than 100-fold better than parental strains, and
corrected the cystic fibrosis epithelial Cl− transport
defect [45]. Furthermore, mouse models were used
to evolve AAV targeting tumors or internal organs
from random peptide display libraries [46,47]. The
animal models demonstrated efficacy in improving
either the transduction efficiency or specificity of
AAV variants, but not both, in these in vivo studies.
A realistic biological model closely mimicking the
environment for gene therapy application would
fulfill the purpose for vector modification more
successfully.
3. Combination of directed evolution and rational
design. Usually directed evolution and rational design
were implemented in parallel for modification of viral
vectors. However, in one recent piece of research,
bioinformatics analysis was used to select a few loops
from the AAV capsid for subsequent semi-random
sequence mutagenesis [43]. The resulting AAV
random loop library was then used for selection of
AAV variants targeting human astrocytes. A second
research group first introduced random mutagenesis
into the GH loop spanning amino acids 390–627 of
the AAV9 capsid [48]. Based on structural analysis,
variants with deleterious mutations were triaged for
further work, and only AAV clones with potentially
beneficial mutations were characterized for vectors
detargeting away from the liver. These two reports
respectively employed bioinformatic clues for
construction of the AAV library and structural
analysis for directed selection of AAV variants, which
may have important implications for directed
evolution work in the future.Conclusions
Over the past few years, AAV has risen to prominence
as a viral vector system in human clinical trials, espe-
cially for the treatment of neurological and muscular
diseases. Furthermore, AAV is also an ideal model for
directed evolution studies because of its relatively simple
genomic structure and the available viral engineering
and production methods. However, there is still scope
for further development and optimization of directed
evolution strategies in modifying this vector. In particu-
lar, the practice of human gene therapy continuously
presents new challenges for AAV and other viral vectors,
such as addressing pre-existing immunity in human
populations [49]. Driven by these needs, we expect fur-
ther advancement in directed evolution of viral vectors,
which will ultimately benefit the biomedical research
and human health.
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